CHRNA6

Across TCGA pan-cancer cohorts, CHRNA6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHRNA6 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CHRNA6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRNA6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, PRAD, and LUAD are the cancer types where CHRNA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	9	view →
PRAD	DFS	Median	All	0.617	0.886	.024	6	view →
LUAD	OS	Median	III,IV	0.068	0.680	<.001	6	view →
UCEC	DFS	Median	All	0.964	0.830	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHRNA6–LUSC (DFS)

Open the LUSC breakdown →